Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
Status:
Withdrawn
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a phase IB study design planned to identify the MTD (Maximum Tolerated Dose) of
Tocilizumab in HCC (Hepatocellular Carcinoma) patients followed by a phase II design
whereupon the primary objective will be median progression free survival (PFS).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center